Genesis Biopharma, Inc. CEO Interviewed on CorporateProfile.com
NEW YORK, NY--(Marketwire - November 12, 2010) - Corporate Profile, LLC announced today that Genesis Biopharma, Inc. (OTCBB: GNBP) CEO, Robert Brooks, was interviewed on CorporateProfile.com.
The video can be viewed at: www.corporateprofile.com.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.
Genesis Biopharma is developing its anti-CD55 antibody therapy to neutralize a key cancer defense mechanism that has been found to be over-expressed in more than 80% of solid tumors. The therapy could provide a safe alternative to toxic chemotherapy regimens. The company is initially addressing metastatic colorectal cancer and lymphoma, and is making progress toward an IND filing with the U.S. Food and Drug Administration (FDA). Genesis Biopharma plans to seek partnerships with pharmaceutical and biotechnology companies to support clinical development programs at the earliest appropriate time. For more information on the company, visit www.genesis-biopharma.com.
About Corporate Profile.com
CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in a unique platform for investors to receive today's hottest tips and market info From New York's top models straight to Wall Street, Corporate Profile's financial models are on the street and in the markets, interviewing CEOs, investment managers, and market gurus about what really drives returns.
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.